This Year's Highlights

• 1. Attracted >$1 million in investment from 9 angel investors of whom 7 are urologists.
• 2. Obtained exclusive options on three key patents from Columbia University and the University of California San Francisco (UCSF).
• 3. Attracted a top flight team of people to manage our development. Team members have all been vice presidents or CEO's of substantial biotech firms. Our Medical Advisory Board consists of four of the top 10 people in the field of sexual dysfunction.

Anticipated Highlights

• 1. Hire a CEO with a strong record of attracting venture capital and driving a biotech company forward. Conversations are underway with two such candidates.
• 2. Complete the acquisition, qualification, and transfer of the cell line that will produce VEGF165. The source of the cell line has been identified and largely qualified. Biocontract manufacturers have been targeted for negotiations.
• 3. Demonstrate that VEGF does not circulate systemically after administration. Such demonstration would greatly smooth the regulatory path; reduce the amount of preclinical work required; and greatly reduce the potential for safety concerns.

Corporate Mission

Geneve Bio develops biotherapeutics to treat and cure sexual dysfunction, a $3 billion, growing market.

We have chosen VEGF165 as our lead product because there is substantial animal work to define efficacy and numerous human clinical trials for other indications to show safety. Whereas existing products are temporary treatments with a large number of failures, we aim for a product that is repairative and restorative and useful for treating patients who fail current therapies.

We will minimize our burn while obtaining high quality direction by recruiting a part-time team of specialists in manufacturing, regulatory, and clinical research that are motivitated by a retainer plus stock options. We will recruit highly qualified contract manufacturers and CRO?s to conduct the work defined by our team.

We intend to sell or license the technology to a major pharmaceutical or biotechnology company after completing at least a Phase I clinical trial within three years and before undertaking any Phase III study. Our intention is to limit our capital raises to no more than two venture rounds.

Overall, our objectives are to:
? Exit at a high valuation in no more than four years
? Focus capital on clinical advancement rather than building infrastructure
? Ensure we have a strong, highly defensible patent position
? Undertake tasks that will make us highly attractive to well-defined strategic acquirers with strong motivation
? Retain a solid, well proven external management team with economic incentives for success.